-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Since March, domestic listed pharmaceutical companies have ushered in the peak of annual report disclosure in 2021.
According to statistics, more than 40 listed pharmaceutical and biological companies have released annual reports
.
From the financial reports disclosed by various pharmaceutical companies, eight pharmaceutical companies achieved a net profit increase of over 100%
.
The eight pharmaceutical companies include Jianmin Group, Teyi Pharmaceutical, Jincheng Pharmaceutical, Lisheng Pharmaceutical, Jimin Medical, Nanotech, Rongchang Bio, and Wantai Bio
.
Jianmin Group released its 2021 performance announcement on March 18.
According to the announcement, in 2021, Jianmin Group’s operating income will increase by 33.
48% year-on-year to 3.
278 billion yuan; its net profit will increase by 119.
73% year-on-year to 325 million yuan
.
It is reported that Jianmin Group’s performance in 2021 will increase mainly due to the increase in the company’s pharmaceutical industry revenue.
Jianmin Group said that in 2021, the company will increase advertising investment and market development efforts, optimize product structure and marketing team building, and achieve OTC Revenue from major product lines and prescription drug product lines increased
.
At present, Jianmin Group and its wholly-owned subsidiary Yekai Thai Pharmaceutical are mainly engaged in the production of pharmaceuticals, and hold a total of 257 pharmaceutical approvals
.
The company's leading product, Longmu Zhuanggu Granules, is a tonic medicine for pediatrics.
In addition, Jianmin Group's main products include Biantong Capsules, Jianmin Throat Tablets, Jianwei Xiaoshi Tablets, Estradiol Gel, and Pudushengji Powder
.
Its wholly-owned subsidiary Yekaitai Health Company develops and operates traditional Chinese medicine and health products
.
Teyi Pharmaceutical released its 2021 performance report on March 15.
According to the report, in 2021, Teyi Pharmaceutical’s operating income will increase by 19.
83% year-on-year to 758 million yuan; its net profit will increase by 189.
66% year-on-year to 127 million yuan.
.
Regarding the performance growth, Teyi Pharmaceutical stated that in 2021, the company will further optimize the product structure, increase internal management, insist on reducing costs and increasing efficiency, and achieved good results during the reporting period; the current national industrial policy strongly supports the traditional Chinese medicine industry Against the background of development, the company focused on the development of Chinese patent medicine varieties this year, and increased the market cultivation and development of potential Chinese patent medicine products while expanding the core products
.
According to the annual report, the gross profit margin of Teyi Pharmaceutical's proprietary Chinese medicine products is as high as 72.
71%
.
Jincheng Pharmaceutical released its 2021 performance report on March 25.
According to the report, in 2021, Jincheng Pharmaceutical’s operating income increased by 5.
96% year-on-year to 3.
138 billion yuan; its net profit increased by 122.
09% year-on-year to 108 million yuan
.
During the reporting period, the market share of the main products of Jincheng Pharmaceutical's intermediates segment remained stable, and the international market of some products increased significantly
.
In terms of biological raw materials, the company seized the changes in the international market demand.
The sales volume and market share of glutathione, adenosylmethionine and other products continued to increase, and the sales volume in the international market grew rapidly.
Domestically, the company completed the completion of butanedisulfoadenosylmethionine, posaconine and other products.
The application of azole was approved by CDE in February 2022; the registration of major customers in India and Russia was completed abroad; the two major bases of chemical raw materials actively deployed production capacity and new product reserves, and at the same time promoted the EU certification of mefenamic acid, FDA certification of posaconazole, Philippine certification of bisoprolol, and submission of certification documents to the United States, Algeria, etc.
, and the initiation of FDA certification of multiple preparation products
.
In terms of preparations, the pharmaceutical preparations segment closely followed the market and policy changes, focusing on "golden antibiotics", "full life cycle gynecological products" and subdivided therapeutic fields; Jincheng Jinsu Cefazolin Sodium and Ceftazidime successfully won the fifth batch of national centralized procurement; Jincheng Taier has comprehensively expanded OTC channels, and its market control and development capabilities have been continuously enhanced
.
Lisheng Pharmaceutical released its 2021 annual performance report on the evening of March 24, saying that its operating income in 2021 will decrease by 4.
29% year-on-year, or about 1.
092 billion yuan; its net profit will increase by 1317.
31% year-on-year, or about 122 million yuan
.
In the context of the comprehensive promotion of the volume-based procurement policy, the sales of Lisheng Pharmaceutical's key and general drug varieties were stable
.
Strengthen the strategic cooperation with the pharmaceutical business leaders, improve the agent management mechanism, and start the development of the second and third terminals with volume varieties
.
Lisheng Pharma also synergistically boosted sales growth, tapped into the potential of primary medical terminals, and strengthened the academic value of products.
The sales volume of Nadroparin Calcium Injection grew strongly year-on-year
.
The company adheres to the market orientation, and effectively promotes the development of OTC and e-commerce business through brand effects, channels and advertising linkages, and achieves continuous sales growth
.
At the same time, Lisheng Pharmaceutical continued to implement the "going out" strategy, actively carried out international registration of products, and achieved a year-on-year increase in product export revenue throughout the year
.
Jimin Medical released the 2021 annual performance report on the evening of March 23.
In 2021, Jimin Medical achieved a year-on-year increase of 25.
16% in operating income, or about 1.
098 billion yuan; net profit increased by 2206.
02% year-on-year, about 148 million yuan; during the reporting period , Jimin Medical, in order to meet the market demand, the company's wholly-owned subsidiary Jumin Bio has newly invested in the construction of 4 production lines for safety syringes (needles).
(Needle) production capacity increased to 850 million per year
.
During the reporting period, under the situation of continuous full production and full sales, the timely expansion of production capacity provided a basic guarantee for the substantial growth of Jimin Medical's performance
.
During the reporting period, the company obtained the safety syringe registration certificate and safety injection needle registration certificate issued by the State Drug Administration, and started the domestic market promotion
.
In the later stage, the company will further adjust production capacity according to market conditions to meet market demand
.
Nano Micro Technology released its 2021 annual report on the evening of March 10.
The announcement shows that in 2021, Nano Micro Technology achieved a year-on-year increase of 118% in revenue to 446 million yuan; net profit increased by 159% year-on-year to 188 million yuan; Deducted non-net profit increased by 172% year-on-year to 172 million yuan
.
During the reporting period, the revenue of Nano Micro Technology's biomedical segment continued to grow, among which the sales of affinity chromatography media, ion exchange chromatography media and other products increased significantly
.
In 2021, Nano Micro Technology's revenue in the biomedical field will be 390 million yuan, a year-on-year increase of 34%, accounting for 87% of revenue, a year-on-year increase of 6 percentage points
.
Rongchang Bio released its 2021 performance report on March 14.
The report shows that in 2021, Rongchang Bio’s net profit will increase by 139.
59% year-on-year to 276 million yuan
.
The announcement stated that the revenue of Rongchang Bio in this year was mainly due to the 131 million yuan in product sales revenue during the commercialization of tacitabine and vedicitumab in China and the confirmation that the company received Seagen for the company's injection of vedic Down payment paid by the cetuximab licensing arrangement
.
Wantai Bio released its 2021 performance report on March 18.
According to the report, in 2021, Wantai Bio achieved a year-on-year increase of 144.
25% in operating income to 5.
75 billion yuan; its net profit increased by 198.
59% year-on-year to 2.
021 billion yuan
.
For the growth in performance, Wantai Bio said that it was mainly due to the increase in revenue from bivalent cervical cancer vaccines, reagents and active raw materials
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
According to statistics, more than 40 listed pharmaceutical and biological companies have released annual reports
.
From the financial reports disclosed by various pharmaceutical companies, eight pharmaceutical companies achieved a net profit increase of over 100%
.
The eight pharmaceutical companies include Jianmin Group, Teyi Pharmaceutical, Jincheng Pharmaceutical, Lisheng Pharmaceutical, Jimin Medical, Nanotech, Rongchang Bio, and Wantai Bio
.
Jianmin Group released its 2021 performance announcement on March 18.
According to the announcement, in 2021, Jianmin Group’s operating income will increase by 33.
48% year-on-year to 3.
278 billion yuan; its net profit will increase by 119.
73% year-on-year to 325 million yuan
.
It is reported that Jianmin Group’s performance in 2021 will increase mainly due to the increase in the company’s pharmaceutical industry revenue.
Jianmin Group said that in 2021, the company will increase advertising investment and market development efforts, optimize product structure and marketing team building, and achieve OTC Revenue from major product lines and prescription drug product lines increased
.
At present, Jianmin Group and its wholly-owned subsidiary Yekai Thai Pharmaceutical are mainly engaged in the production of pharmaceuticals, and hold a total of 257 pharmaceutical approvals
.
The company's leading product, Longmu Zhuanggu Granules, is a tonic medicine for pediatrics.
In addition, Jianmin Group's main products include Biantong Capsules, Jianmin Throat Tablets, Jianwei Xiaoshi Tablets, Estradiol Gel, and Pudushengji Powder
.
Its wholly-owned subsidiary Yekaitai Health Company develops and operates traditional Chinese medicine and health products
.
Teyi Pharmaceutical released its 2021 performance report on March 15.
According to the report, in 2021, Teyi Pharmaceutical’s operating income will increase by 19.
83% year-on-year to 758 million yuan; its net profit will increase by 189.
66% year-on-year to 127 million yuan.
.
Regarding the performance growth, Teyi Pharmaceutical stated that in 2021, the company will further optimize the product structure, increase internal management, insist on reducing costs and increasing efficiency, and achieved good results during the reporting period; the current national industrial policy strongly supports the traditional Chinese medicine industry Against the background of development, the company focused on the development of Chinese patent medicine varieties this year, and increased the market cultivation and development of potential Chinese patent medicine products while expanding the core products
.
According to the annual report, the gross profit margin of Teyi Pharmaceutical's proprietary Chinese medicine products is as high as 72.
71%
.
Jincheng Pharmaceutical released its 2021 performance report on March 25.
According to the report, in 2021, Jincheng Pharmaceutical’s operating income increased by 5.
96% year-on-year to 3.
138 billion yuan; its net profit increased by 122.
09% year-on-year to 108 million yuan
.
During the reporting period, the market share of the main products of Jincheng Pharmaceutical's intermediates segment remained stable, and the international market of some products increased significantly
.
In terms of biological raw materials, the company seized the changes in the international market demand.
The sales volume and market share of glutathione, adenosylmethionine and other products continued to increase, and the sales volume in the international market grew rapidly.
Domestically, the company completed the completion of butanedisulfoadenosylmethionine, posaconine and other products.
The application of azole was approved by CDE in February 2022; the registration of major customers in India and Russia was completed abroad; the two major bases of chemical raw materials actively deployed production capacity and new product reserves, and at the same time promoted the EU certification of mefenamic acid, FDA certification of posaconazole, Philippine certification of bisoprolol, and submission of certification documents to the United States, Algeria, etc.
, and the initiation of FDA certification of multiple preparation products
.
In terms of preparations, the pharmaceutical preparations segment closely followed the market and policy changes, focusing on "golden antibiotics", "full life cycle gynecological products" and subdivided therapeutic fields; Jincheng Jinsu Cefazolin Sodium and Ceftazidime successfully won the fifth batch of national centralized procurement; Jincheng Taier has comprehensively expanded OTC channels, and its market control and development capabilities have been continuously enhanced
.
Lisheng Pharmaceutical released its 2021 annual performance report on the evening of March 24, saying that its operating income in 2021 will decrease by 4.
29% year-on-year, or about 1.
092 billion yuan; its net profit will increase by 1317.
31% year-on-year, or about 122 million yuan
.
In the context of the comprehensive promotion of the volume-based procurement policy, the sales of Lisheng Pharmaceutical's key and general drug varieties were stable
.
Strengthen the strategic cooperation with the pharmaceutical business leaders, improve the agent management mechanism, and start the development of the second and third terminals with volume varieties
.
Lisheng Pharma also synergistically boosted sales growth, tapped into the potential of primary medical terminals, and strengthened the academic value of products.
The sales volume of Nadroparin Calcium Injection grew strongly year-on-year
.
The company adheres to the market orientation, and effectively promotes the development of OTC and e-commerce business through brand effects, channels and advertising linkages, and achieves continuous sales growth
.
At the same time, Lisheng Pharmaceutical continued to implement the "going out" strategy, actively carried out international registration of products, and achieved a year-on-year increase in product export revenue throughout the year
.
Jimin Medical released the 2021 annual performance report on the evening of March 23.
In 2021, Jimin Medical achieved a year-on-year increase of 25.
16% in operating income, or about 1.
098 billion yuan; net profit increased by 2206.
02% year-on-year, about 148 million yuan; during the reporting period , Jimin Medical, in order to meet the market demand, the company's wholly-owned subsidiary Jumin Bio has newly invested in the construction of 4 production lines for safety syringes (needles).
(Needle) production capacity increased to 850 million per year
.
During the reporting period, under the situation of continuous full production and full sales, the timely expansion of production capacity provided a basic guarantee for the substantial growth of Jimin Medical's performance
.
During the reporting period, the company obtained the safety syringe registration certificate and safety injection needle registration certificate issued by the State Drug Administration, and started the domestic market promotion
.
In the later stage, the company will further adjust production capacity according to market conditions to meet market demand
.
Nano Micro Technology released its 2021 annual report on the evening of March 10.
The announcement shows that in 2021, Nano Micro Technology achieved a year-on-year increase of 118% in revenue to 446 million yuan; net profit increased by 159% year-on-year to 188 million yuan; Deducted non-net profit increased by 172% year-on-year to 172 million yuan
.
During the reporting period, the revenue of Nano Micro Technology's biomedical segment continued to grow, among which the sales of affinity chromatography media, ion exchange chromatography media and other products increased significantly
.
In 2021, Nano Micro Technology's revenue in the biomedical field will be 390 million yuan, a year-on-year increase of 34%, accounting for 87% of revenue, a year-on-year increase of 6 percentage points
.
Rongchang Bio released its 2021 performance report on March 14.
The report shows that in 2021, Rongchang Bio’s net profit will increase by 139.
59% year-on-year to 276 million yuan
.
The announcement stated that the revenue of Rongchang Bio in this year was mainly due to the 131 million yuan in product sales revenue during the commercialization of tacitabine and vedicitumab in China and the confirmation that the company received Seagen for the company's injection of vedic Down payment paid by the cetuximab licensing arrangement
.
Wantai Bio released its 2021 performance report on March 18.
According to the report, in 2021, Wantai Bio achieved a year-on-year increase of 144.
25% in operating income to 5.
75 billion yuan; its net profit increased by 198.
59% year-on-year to 2.
021 billion yuan
.
For the growth in performance, Wantai Bio said that it was mainly due to the increase in revenue from bivalent cervical cancer vaccines, reagents and active raw materials
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
